Vertex Pharmaceuticals Tax Reconciliation - Tax Exempt Income remained flat by 0.0% to $0.00 in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 94.9%, from $0.06 to $0.00. Over 2 years (FY 2023 to FY 2025), Tax Reconciliation - Tax Exempt Income shows an upward trend with a 27.5% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
A higher value indicates a greater benefit from tax-exempt income sources, improving net profitability.
The tax effect of income that is exempt from taxation, expressed as a reconciliation item to the statutory tax rate. Thi...
Standard component of the effective tax rate reconciliation table for companies with significant investment income.
ms_tax_reconciliation_tax_exempt_income| FY'23 | FY'24 | FY'25 | |
|---|---|---|---|
| Value | $0.01 | $0.26 | $0.01 |
| YoY Change | — | >999% | -94.9% |